Assistant Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Francis K. Buadi, MD
|
|
Give Review
Francis K. Buadi is an expert in the field of Hematology. He studied medicine at University of Science and Technology School of Medicine. He over the years received 4 awards: "Fellows Program", "Fellows/Mentors Program", "Honors in Physiology/Biochemistry" and "Best All Round Student, Advanced Level". Francis Buadi is a published physician. He has 101 papers published. The most current publication "First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis." Doctor Francis K. Buadi, MD is registered with Medicare and accepts Medicare payments.
Publications
- The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple Myeloma.
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Effective use of panobinostat in combination with other active agents in Myeloma in a novel 5-drug combination: Case Report and Interesting Observations.
- Utility of immunophenotyping of plasma cells in multiple Myeloma.
- Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple Myeloma.
- Treatment outcomes, healthcare resource utilization, and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myel...
- Soluble suppression of tumorigenicity 2 (sST2), but not Galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and Tropo...
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed Myeloma.
- Quantification of clonal circulating plasma cells in relapsed multiple Myeloma.
- A phase 1/2 study of an adjuvanted varicella-zoster virus subunit candidate vaccine in adult autologous hematopoietic stem-cell transplant recipients.
- Long-term outcome of patients with multiple Myeloma-related advanced renal failure following auto-SCT.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- Quantification of clonal circulating plasma cells in newly diagnosed multiple Myeloma: implications for redefining high-risk Myeloma.
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
- Potential new risks of lenalidomide.
- Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple Myeloma following lenalidomide-based initial therapy.
- Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification.
- Long term response to lenalidomide in patients with newly diagnosed multiple Myeloma.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict EnGraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cel...
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Implications of continued response after autologous stem cell transplantation for multiple Myeloma.
- A detailed evaluation of the current Renal response criteria in AL amyloidosis: is it time for a revision?
- Outcomes of patients with POEMS syndrome treated initially with radiation.
- Treatment outcomes in patients with relapsed and refractory multiple Myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple Myeloma.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myelom...
- Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.
- Second auto-SCT for treatment of relapsed multiple Myeloma.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
- The diagnosis and characteristics of Renal heavy-chain and heavy/light-chain amyloidosis and their comparison with Renal light-chain amyloidosis.
- Localized insulin-derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate.
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- What do I need to know about immunoglobulin light chain (AL) amyloidosis?
- Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
- Trisomies in multiple Myeloma: impact on survival in patients with high-risk cytogenetics.
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
- Immunoglobulin D amyloidosis: a distinct entity.
- The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
- Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory Disease.
- Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple Myeloma.
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple Myeloma.
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple Myeloma.
- Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.
- High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa.
- SCT without growth factor in multiple myeloma: enGraftment kinetics, bacteremia and hospitalization.
- Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.
- Incidence of extramedullary Disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
- Treatment of immunoglobulin light chain (primary or AL) amyloidosis.
- Long-term outcomes of patients with light chain amyloidosis (AL) after Renal transplantation with or without stem cell transplantation.
- Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple Myeloma (SMM).
- Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Multiple Myeloma with concomitant JAK2-positive essential thrombocythemia post-successful autologous peripheral blood hematopoietic stem cell transplant.
- Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
- Low risk of symptomatic Venous thromboembolic events during growth factor administration for PBSC mobilization.
- IgM Amyloidosis: Clinical Features in Therapeutic Outcomes.
- Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.
- Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple Myeloma and smoldering ...
- Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
- Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple Myeloma (MM).
- Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing d...
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple Myeloma in the era of novel therapie.
- A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple Myeloma.
- Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into Disease biology in patients with POEMS syndrome.
- Plasma cell Leukemia.
- Stem cell transplantation in multiple Myeloma: impact of response failure with thalidomide or lenalidomide induction.
- Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis.
- Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple Myeloma.
- Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple Myeloma.
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple Myeloma: a comparative analysis of 411 patients.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple Myeloma may be associated with prolonged survival.
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple Myeloma.
- Clinical outcome of immunoglobulin light chain amyloidosis affecting the Kidney.
- Echocardiographic features of cardiac amyloidosis presenting as endomyocardial Disease in a 54-year-old male.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple Myeloma.
- Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple Myeloma.
- Transplantation for IgM amyloidosis and IgM Myeloma.
- Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
- Induction of a Chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the...
- Does stem cell transplantation have a role in the management of multiple Myeloma, 2009?
- A novel report of cig-FISH and cytogenetics in POEMS syndrome.
- Autologous stem cell transplant in 716 patients with multiple Myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Impact of early relapse after auto-SCT for multiple Myeloma.
- Autologous stem cell transplantation in patients of 70 years and older with multiple Myeloma: Results from a matched pair analysis.
- Impact of pretransplant therapy in patients with newly diagnosed Myeloma undergoing autologous SCT.
- Plasmablastic Lymphoma in a previously undiagnosed AIDS patient: a case report.
- First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis.
Schools
Kwame Nkrumah University Of Science Technology School Of Medical Sciences
St Agnes Hospital
University MD
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Fellows Program
- Fellows/Mentors Program
- Honors in Physiology/Biochemistry
- Best All Round Student, Advanced Level
Education
-
Mayo School of Graduate Medical Education -
University of Maryland -
University of Science and Technology School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1770575185 | |
| NPPES Provider LastName | BUADI | |
| NPPES Provider FirstName | FRANCIS | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology | |
| Total Claim Count | 431.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770575185 |
| Last Name Of The Provider | BUADI |
| First Name Of The Provider | FRANCIS |
| View All |
Similar Doctors
|
|
Dr. Rajiv K. Pruthi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. S Vincent Rajkumar, MD |
|
|
Dr. Patrick B. Johnston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kiernan J. Minehan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary A. Croghan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward T. Creagan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manish Kohli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aneel A. Ashrani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arleigh B. Robertson McCurdy, MD |
|
|
Dr. Lijo Simpson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert R. McWilliams, MD |
|
|
Dr. Linda N. Dao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Bram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge F. Quevedo, MD
This Doctor is OpenDoctor Recommended.
|